Giant cell tumor of bone in childhood: Clinical aspects and novel therapeutic targets

Pediatric Drugs

Volumn 16, Issue 1, 2014, Pages 21-28

  Federman, Noah ^a,b   Brien, Earl W ^c   Narasimhan, Vivek ^d   Dry, Sarah M ^b   Sodhi, Monish ^d   Chawla, Sant P ^d  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d Sarcoma Oncology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; INTERFERON; NUCLEAR FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; MONOCLONAL ANTIBODY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ARTHRALGIA; ARTICLE; BONE METASTASIS; CHILDHOOD CANCER; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MOLECULAR PATHOLOGY; MUSCULOSKELETAL PAIN; OSTEOCLASTOMA; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SOLID TUMOR; BONE TUMOR; DRUG ANTAGONISM; INFANT; METABOLISM; PATHOLOGY; PRESCHOOL CHILD;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; CHILD, PRESCHOOL; GIANT CELL TUMOR OF BONE; HUMANS; INFANT; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 84897572133     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0051-3     Document Type: Article

References (46)

1. Coopers AS, Travers B. Surgical essays. London: Cox Longman and Co.; 1818.
2. Turcotte RE. Giant cell tumor of bone. Orthop Clin N Am. 2006;37(1):35-51. (Pubitemid 41719085)
3. Larsson SE, Lorentzon R, Boquist L. Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish Cancer Registry for the years 1958 through 1968. J Bone Jt Surg Am. 1975;57(2):167-73.
4. Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol. 2009;21(4):338-44.
5. Kransdorf MJ, Sweet DE, Buetow PC, Giudici MA, Moser RP Jr. Giant cell tumor in skeletally immature patients. Radiology. 1992;184(1):233-7.
6. Picci P, Manfrini M, Zucchi V, Gherlinzoni F, Rock M, Bertoni F, et al. Giant-cell tumor of bone in skeletally immature patients. J Bone Jt Surg Am. 1983;65(4):486-90. (Pubitemid 13125099)
7. Schutte HE, Taconis WK. Giant cell tumor in children and adolescents. Skelet Radiol. 1993;22(3):173-6. (Pubitemid 23184765)
8. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Jt Surg Am. 1987;69(1):106-14. (Pubitemid 17030377)
9. Murphey MD, Nomikos GC, Flemming DJ, Gannon FH, Temple HT,KransdorfMJ. Fromthe archives of theAFIP-imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. Radiographics. 2001;21(5):1283-309. (Pubitemid 33707238)
10. Mii Y, Miyauchi Y, Morishita T, Miura S, Honoki K, Aoki M, et al. Osteoclast origin of giant-cells in giant-cell tumors of bone-ultrastructural and cytochemical study of 6 cases. Ultrastruct Pathol. 1991;15(6):623-9.
11. Atkins GJ, Kostakis P, Vincent C, Farrugia AN, Houchins JP, Findlay DM, et al. RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res. 2006;21(9):1339-49. (Pubitemid 44300040)
12. Morgan T, Atkins GJ, Trivett MK, Johnson SA, Kansara M, Schlicht SL, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappa B. Am J Pathol. 2005;167(1):117-28. (Pubitemid 40884775)
13. Cowan RW, Singh G. Giant cell tumor of bone: a basic science perspective. Bone. 2013;52(1):238-46.
14. Knowles HJ, Athanasou NA. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol. 2008;215(1):56-66. (Pubitemid 351619876)
15. Gitelis S, Mallin BA, Piasecki P, Turner F. Intralesional excision compared with en-bloc resection for giant-cell tumors of bone. J Bone Jt Surg Am Vol. 1993;75A(11):1648-55. (Pubitemid 24036441)
16. Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ. Giant cell tumor of bone. J Am Acad Orthop Sur. 2013;21(2):118-26.
17. Gouin F, Dumaine V, the French Sarcoma and Bone Tumor Study Groups (GSF-GETO). Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups). Orthop Traumatol Surg Res. Epub 2013 Aug 23.
18. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone risk factors for recurrence. Clin Orthop Relat Res. 2011;469(2):591-9.
19. Feigenberg SJ, Marcus RB, Zlotecki RA, Scarborough MT, Berrey BH, Enneking WF. Radiation therapy for giant cell tumors of bone. Clin Orthop Relat R. 2003;(411):207-16.
20. Shi W, Indelicato DJ, Morris CG, Scarborough MT, Gibbs CP, Mendenhall WM, et al. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol. 2010;78(3):S616-7.
21. Caudell JJ, Ballo MT, Zagars GK, Lewis VO, Weber KL, Lin PP, et al. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol. 2003;57(1):158-65. (Pubitemid 36959751)
22. Thangaraj R, Grimer RJ, Carter SR, Stirling AJ, Spilsbury J, Spooner D. Giant cell tumour of the sacrum: a suggested algorithm for treatment. Eur Spine J. 2010;19(7):1189-94.
23. Shen CC, Li H, Shi ZL, Tao HM, Yang ZM. Current treatment of sacral giant cell tumour of bone: a review. J Int Med Res. 2012;40(2):415-25.
24. Balke M, Streitbuerger A, Budny T, Henrichs M, Gosheger G, Hardes J. Treatment and outcome of giant cell tumors of the pelvis 20 cases followed for 1 to 11 years. Acta Orthop. 2009;80(5):590-6.
25. Lin PP, Guzel VB, Moura MF, Wallace S, Benjamin RS, Weber KL, et al. Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer. 2002;95(6):1317-25. (Pubitemid 35013068)
26. Ashraf MS, Gururangan S, Breatnach F. Benign giant cell tumour of bone in a child with pulmonary metastases at presentation. Eur J Surg Oncol. 1994;20(6):700-2.
27. Skubitz KM, Manivel JC. Giant cell tumor of the uterus: case report and response to chemotherapy. BMC Cancer. 2007;7:46.
28. Balke M, Campanacci L, Gebert C, Picci P, Gibbons M, Taylor R, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer. 2010;10:462.
29. Wei F, Liu XG, Liu ZJ, Jiang LA, Dang GT, Ma QJ, et al. Interferon alfa-2b for recurrent and metastatic giant cell tumor of the spine report of two cases. Spine. 2010;35(24):E1418-22.
30. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-31. (Pubitemid 43290920)
31. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-32.
32. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized double-blind study. J Clin Oncol. 2010;28(35):5132-9.
33. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-22.
34. FDA. Highlights of prescribing information Xgeva (denosumab), Amgen, Thousand Oaks, California. 2013.
35. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275-80.
36. Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012;18(16):4415-24.
37. Epstein MS, Ephros HD, Epstein JB. Review of current literature and implications of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol. Epub 2012 Aug 15.
38. Balke M, Hardes J. Denosumab: a breakthrough in treatment of giant-cell tumour of bone? Lancet Oncol. 2010;11(3):218-9.
39. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901-8.
40. Blay JY, Chawla S, Seeger L, Henshaw R, Choy E, Grimer R, et al. Safety and efficacy of denosumab for giant cell tumor of bone. Connective Tissue Oncology Society Meeting, Prague. 2012.
41. Broto JM Cleeland C, Skubitz K, Staddon A, Blum R, Dominkus M, et al. The effects of denosumab on pain and analgesic use in giant cell tumor of bone (GCTB): updated results from a phase 2 study. Connective Tissue Oncology Society Meeting, Prague. 2012.
42. Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2012;12(3):183-8.
43. Shroff R, Beringer O, Rao K, Hofbauer LC, Schulz A. Denosumab for post-transplantation hypercalcemia in osteopetrosis. N Engl J Med. 2012;367(18):1766-7.
44. Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res. 2012;27(7):1462-70.
45. Lange T, Stehling C, Fröhlich B, Klingenhofer M, Kunkel P, Schneppenheim R, et al. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J. 2013;22(6):1417-22.
46. Karras NA, Polgreen LE, Ogilvie C, Manivel JC, Skubitz KM, Lipsitz E. Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. J Clin Oncol. 2013;31(12):e200-2.